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Although the brain is now known to actively interact with the immune system under 
non-inflammatory conditions, the site of cell–cell interactions between brain parenchy-
mal cells and immune cells has been an open question until recently. Studies by our and 
other groups have indicated that brain structures such as the leptomeninges, choroid 
plexus stroma and epithelium, attachments of choroid plexus, vascular endothelial cells, 
cells of the perivascular space, circumventricular organs, and astrocytic endfeet con-
struct the histological architecture that provides a location for intercellular interactions 
between bone marrow-derived myeloid lineage cells and brain parenchymal cells under 
non-inflammatory conditions. This architecture also functions as the interface between 
the brain and the immune system, through which systemic inflammation-induced 
molecular events can be relayed to the brain parenchyma at early stages of systemic 
inflammation during which the blood–brain barrier is relatively preserved. Although brain 
microglia are well known to be activated by systemic inflammation, the mechanism by 
which systemic inflammatory challenge and microglial activation are connected has not 
been well documented. Perturbed brain–immune interaction underlies a wide variety of 
neurological and psychiatric disorders including ischemic brain injury, status epilepticus, 
repeated social defeat, and neurodegenerative diseases such as Alzheimer’s disease 
and Parkinson’s disease. Proinflammatory status associated with cytokine imbalance 
is involved in autism spectrum disorders, schizophrenia, and depression. In this article, 
we propose a mechanism connecting systemic inflammation, brain–immune interface 
cells, and brain parenchymal cells and discuss the relevance of basic studies of the 
mechanism to neurological disorders with a special emphasis on sepsis-associated 
encephalopathy and preterm brain injury.
Keywords: choroid plexus, leptomeninges, bone marrow transplantation, endotoxemia, cytokine, sepsis-
associated encephalopathy, preterm brain injury
introdUCtion
The central nervous system (CNS) used to be regarded as an immune-privileged organ (1). CNS 
immune privilege was experimentally defined by the fact that tissues that were rapidly rejected by 
the immune system when grafted in sites such as the skin, showed prolonged survival when grafted 
into the CNS (2). Isolation of the brain from the immune system by the blood–brain barrier (BBB) 
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and the lack of draining lymphatics also contributed to the idea 
of brain immune privilege (3).
However, recent data have dramatically altered such a view-
point by demonstrating that the CNS interacts actively with the 
peripheral immune system and is therefore immune competent. 
Interactions between the CNS and the peripheral immune system 
are achieved via humoral factors, nerve fibers, and cell–cell inter-
actions under both non-inflammatory and inflammatory condi-
tions. In this article, we will focus on the tissue architecture and 
cellular components that enable cell–cell interactions between 
the brain and the immune systems in organisms. We discuss how 
these interactions are relevant to neurological diseases in which 
systemic inflammation underlies the pathogenesis.
neW aspeCts oF tHe Brain–iMMUne 
systeM interaCtion
The immune system plays an important role in maintaining the 
higher brain functions under non-inflammatory conditions. For 
example, severe combined immune deficiency mice and nude 
mice that are deficient in mature T cells exhibit cognitive deficits 
and behavioral abnormalities that are remedied by T cell restora-
tion (4). Systemic depletion of CD4+ T cells leads to reduced 
hippocampal neurogenesis and impaired learning in the Morris 
water maze (5). Although there are no T cells present in the 
healthy brain parenchyma under non-inflammatory conditions, 
T cells accumulate in the meninges and express high levels of 
interleukin (IL)-4, which skews meningeal myeloid cells toward 
an anti-inflammatory phenotype during cognitive task perfor-
mance (6, 7).
The so-called glymphatic system is a brain-wide perivascular 
pathway that consists of a paraarterial cerebrospinal fluid (CSF) 
influx route, a paravenous interstitial fluid clearance route, and 
an intracellular trans-astrocytic path that is mediated via aqua-
porin-4 (8, 9). The glymphatic system supports the exchange of 
CSF with interstitial fluid and plays a role in driving waste products 
by way of vectorial convective flow from the interstitium toward 
the paravenous space, where waste products may gain access 
to lymphatic vessels in the neck (8). Interestingly, natural sleep 
or anesthesia increases the volume of interstitial space by 60%, 
resulting in a remarkable increase in convective exchange of CSF 
with interstitial fluid, which propels the clearance of potentially 
neurotoxic waste products such as Aβ oligomers that accumulate 
during wakefulness (10).
More recently, functional lymphatic vessels that line the dural 
sinuses have been discovered by two groups independently (11, 
12). These sinus-associated lymphatic vessels are able to carry 
both fluid and immune cells from the CSF (11). The dural lym-
phatic vessels absorb CSF from the adjacent subarachnoid space 
and brain interstitial fluid via the glymphatic system (12). Dural 
lymphatic vessels transport fluid into deep cervical lymph nodes 
via foramina at the base of the skull. Therefore, the dural lymphatic 
vessels and glymphatic system may act together to drive Aβ from 
the brain (13). In addition, the dural lymphatic system presum-
ably provides architecture that supports immune cell dynamics 
during the performance of higher functions of the brain under 
non-inflammatory conditions. In this regard, impaired functions 
of the glymphatic system or dural lymphatic system may cause 
neurodegenerative dementia such as Alzheimer’s disease (AD).
sites oF interCeLLULar interaCtion 
BetWeen Brain CeLLs and iMMUne 
CeLLs
Bone Marrow transplantation (BMt) to 
search for the Brain–immune interface
Although the brain is now known to actively interact with the 
immune system under non-inflammatory conditions, the site 
of cell–cell interaction between brain parenchymal cells and 
immune cells remains an open question. It was reported that 
following BMT by intravenous injection of donor cells, donor-
derived cells were distributed throughout the brain parenchyma, 
and differentiated into ramified microglia (14, 15). However, it 
is now recognized that postnatal hematopoietic progenitors do 
not significantly contribute to microglia renewal or homeostasis 
in the adult brain (16). Other investigators have claimed that the 
donors’ bone marrow-derived cells are found chiefly in asso-
ciation with blood vessels and are only rarely found in the brain 
parenchyma (17–19).
A novel BMT procedure has since been developed that is 
called “intra-bone marrow (IBM)-BMT” (20). In this procedure, 
BMCs are collected from the marrow of the donors’ long bones 
by perfusion, and the entire BMCs are injected directly into the 
bone marrow cavity of the recipients instead of being injected 
intravenously (20, 21). The advantage of this IBM procedure is 
that it facilitates the transplantation of mesenchymal stem cells 
(MSCs) as well as of hematopoietic stem cells (HSCs) from the 
donor into the recipient (22). Two to six days after BMT, higher 
numbers of both HSCs and MSCs were reported in the bone 
marrow cavity of chimeras prepared by using the IBM procedure 
than those resulting from a conventional intravenous procedure 
(23–28).
Leptomeninges, Choroid plexus stroma, 
perivascular space, and Circumventricular 
organs (CVos) as Brain–immune 
interfaces
In our first set of experiments described in the present article that 
has been originally published in Ref. (29), we used bone marrow-
chimeric mice prepared by the IBM procedure to investigate the 
distribution and time-dependent changes in the density of bone 
marrow-derived cells as well as in their differentiation in the 
brain under non-inflammatory conditions (29). Bone marrow-
derived cells start to appear in the leptomeninges and choroid 
plexus stroma at 2 weeks after BMT, and to appear in the brain 
perivascular spaces at 4  weeks after BMT in the bone marrow 
chimera. In the leptomeninges, bone marrow-derived cells 
exhibit round or spindle-shaped morphology. Spindle-shaped 
cells are located along the pia and in close apposition to subpial 
astrocytic endfeet. Bone marrow-derived cells that have entered 
the perivascular space, which is a narrow space between the outer 
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surface of capillary walls and the brain parenchymal surface, are 
situated in close apposition to perivascular astrocytic endfeet. 
In the choroid plexus stroma, bone marrow-derived cells with 
a round to ovoid morphology often appear in clusters. Isolated, 
scattered bone marrow-derived cells exhibit a spindle-shaped 
morphology without ramified processes. Importantly, leptome-
ninges, perivascular spaces, and choroid plexus stroma share 
tissue components that are contiguous due to the fact that these 
brain regions are derived from the same developmental origin. 
Therefore, these spaces are one of the major interfaces between 
the immune system and the brain.
At 1  month after BMT, bone marrow-derived cells enter 
structures that lack a BBB and that are collectively named CVOs, 
including structures such as the median eminence, posterior 
pituitary, subfornical organ, pineal gland, and area postrema. 
Most bone marrow-derived cells in the CVOs are closely associ-
ated with blood vessels and exhibit elongated cell bodies with rare 
ramified processes. Therefore, CVOs are also interfaces between 
the immune system and the brain.
the attachments of Choroid plexus  
as a novel Brain–immune interface
A group of brain regions that has not been a focus of attention 
from scientists in the field is a group of particular brain paren-
chymal regions that is populated by bone marrow-derived cells 
(29). These regions are relatively small in size and discrete. Bone 
marrow-derived cells in these particular regions frequently 
exhibit multiple ramified processes (ramified marrow-derived 
cells). All ramified marrow-derived cells express Iba-1, a 
marker for myeloid cells (monocyte/macrophage lineage) (29). 
None of the ramified marrow-derived cells express markers 
for astrocytes, oligodendrocytes, or neurons. In chimeric mice 
in which the IBM procedure is used, most of these ramified 
marrow-derived cells start to appear at 4 months after BMT. The 
density of ramified marrow-derived cells increases thereafter, as 
a function of post-BMT time, for up to 8 months, which is the 
longest time point that we have examined so far (29). Ramified 
marrow-derived cells are distributed with the highest density 
(>16 cells/mm2) in the habenula and the brain stem cochlear 
nucleus, followed by the medial amygdala and the bed nucleus 
of stria terminalis (8–16 cells/mm2). They are distributed with 
moderate densities (4–8  cells/mm2) in the piriform cortex, 
thalamus, and cerebellar cortex. In the ventral hippocampus, 
superior colliculus, hypothalamus, and midbrain tegmentum, 
ramified marrow-derived cells are distributed at relatively low 
densities (2–4  cells/mm2). The regions populated by ramified 
marrow-derived cells contain junctions at which the choroid 
plexus is attached to the brain parenchyma (29). In the lateral 
ventricle, the choroid plexus is formed by papillary protrusion 
of the leptomeninges toward the inside of the ventricular cavity, 
where they bridge the stria terminalis and medial amygdala. 
The choroid plexus stroma shares tissue components with the 
leptomeninges and consists of loose connective tissue contain-
ing many capillaries. The choroid plexus epithelial cells are a 
continuation of the ependymal cells. At the edge of the stria ter-
minalis or medial amygdala, the brain parenchyma is extremely 
thin and consists of loose wavy fibrous processes of astrocytes 
that are located in the narrow channel between the ependyma 
and the pia (Figure  1). We call this particular structure that 
consists of ependyma, loose glial tissue, and pia that connects 
the brain parenchyma and the choroid plexus the “attachments 
of choroid plexus.”
Bone marrow-derived cells exhibit a round to ovoid morphol-
ogy in the choroid plexus stroma, whereas bone marrow-derived 
cells are spindle-shaped and often exhibit a tortuous appear-
ance when they are inside the attachments of choroid plexus. 
Once these cells enter the brain parenchyma, they cluster in a 
relatively small area and differentiated into ramified morphology 
(Figure 2) (30). These observations raise the possibility that bone 
marrow-derived cells enter the brain parenchyma through the 
attachments of choroid plexus. The sites of intercellular interac-
tion between brain cells and immune cells that are based on the 
results of our IBM-BMT studies are summarized in a cartoon 
illustration in Figure 3.
There are presumably some molecular cues that enhance 
the migration of bone marrow-derived cells from the choroid 
plexus to the brain parenchyma. One such candidate cues is the 
CX3CL1–CX3CR1 signaling system. CX3CL1 (or fractalkine) is 
strongly expressed in the attachments of choroid plexus in both 
BM-transplanted and non-treated mice in a similar manner (30). 
CX3CL1 is constitutively expressed in a portion of the elongated 
cytoplasmic processes that emanate from astrocytes whose cell 
bodies are located in the adjacent brain parenchyma. Monocyte-
derived cells in the choroid plexus and microglia in the brain 
parenchyma are known to express CX3CR1 (32), which is a highly 
specific receptor for CX3CL1 (33). CX3CL1 is a transmembrane 
molecule with a unique CX3C motif whose expression is induced 
by inflammatory cytokines (34). In addition to its functions as 
a cell adhesion molecule (33), membrane-anchored CX3CL1 
can be released from the cell surface by cleavage and shedding 
mediated by A Disintegrin And Metalloproteinase (ADAM)10 
and ADAM17 (35, 36). Once released, soluble CX3CL1 functions 
as a chemoattractant for cells bearing CX3CR1 (33, 34). The 
CX3CL1–CX3CR1 signaling system is also known to be required 
for physiological trafficking of circulating monocytes to periph-
eral organs such as lung (37) and small intestine (38). Therefore, 
bone marrow-derived cells that are in the process of lining up 
along the narrow channel of the attachments of choroid plexus 
may make cell–cell contact with astrocytic processes that express 
CX3CL1, resulting in their trafficking into brain parenchyma.
endotoXeMia-indUCed  
CytoKine-Mediated responses oF 
HippoCaMpaL astroCytes 
transMitted By CeLLs oF tHe  
Brain–iMMUne interFaCe
endotoxemia-induced impairments in 
Brain Higher Functions
The immune system modulates the functional and behavioral 
processes of the CNS under inflammatory conditions (39). 
Exposure to pathogens such as lipopolysaccharide (LPS) stimu-
lates the peripheral immune system and induces inflammatory 
FigUre 2 | photoimages indicating changes in the morphology of bone marrow-derived cells in the brain. In the choroid plexus stroma, bone  
marrow-derived cells exhibit a round to ovoid morphology (a). When bone marrow-derived cells are located inside the attachments of choroid plexus, they are 
spindle-shaped and often exhibit a tortuous appearance with sharp bends (B). Once these cells enter the brain parenchyma, they differentiate into a ramified 
morphology (C). Immunohistochemical staining with an anti-GFP antibody. Nuclei are counterstained with hematoxylin. This figure is a modification of copyrighted 
material permitted by Academic Press (29), License Id: 3917441104164.
FigUre 1 | schematic illustration of choroid plexus morphogenesis. (a,B) The neural tube contains the future cerebral ventricle and that the leptomenix is 
derived from the neural crest. In particular parts of the neural tube, the cerebral ventricle is shifted to the dorsal end of the brain parenchyma, from which the choroid 
plexus is formed. (C) An enlarged view of the square inset indicated in panel (B). The choroid plexus is formed as a papillary protrusion of the subarachnoid stromal 
tissue (d). Therefore, the choroid plexus stroma shares tissue components with the subarachnoid space and consists of loose connective tissue containing many 
capillary blood vessels. The choroid plexus epithelium is a continuation of the ependyma. At the edge of the choroid plexus, the brain parenchyma is extremely thin 
and located in a narrow channel between the ependyma and pia (arrow head). We call this particular structure the “attachments of choroid plexus.” The real 
histological architecture that is represented by the schema in panel (d) is indicated by a photoimage of a paraffin-embedded section of the mouse choroid plexus 
from the third ventricle stained with hematoxylin and eosin (e). Note the presence of the “attachments of choroid plexus” in both sides (*).
4
Shimada and Hasegawa-Ishii Brain–Immune Cell–Cell Interaction
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 17
responses with the elevation of proinflammatory cytokines such 
as IL-1 (40, 41), IL-6, and tumor necrosis factor (TNF)-α (42). 
Increased levels of proinflammatory cytokines in peripheral 
tissues lead to the local synthesis of proinflammatory cytokines 
within the brain parenchyma (43–45), resulting in behavioral 
alterations such as sickness behavior (46–48), impaired learning 
(49), and depressive-like behavior in mice (50).
The hippocampus is one of the targets for behavioral changes 
induced by systemic inflammatory challenge. Types of memory 
tasks sensitive to peripheral LPS administration including a 
FigUre 3 | schematic illustration of the sites of brain–immune cell–cell interaction. Red-colored cells represent bone marrow-derived myeloid cells that are 
located in the subarachnoid space [1], perivascular space [2], and choroid plexus stroma [3], all of which are contiguous. Bone marrow-derived cells enter the 
subarachnoid space through fenestrated blood vessels and can be localized in close apposition to the pia and subpial astrocytic endfeet that are a part of the brain 
parenchyma. Marrow-derived cells in the perivascular space can be localized in close apposition to perivascular astrocytic endfeet. Marrow-derived cells can cross 
the loose blood vessel walls of the circumventricular organs [4] and enter the parenchyma. Marrow-derived cells in the choroid plexus stroma can migrate into the 
brain parenchyma thorough the attachments of choroid plexus (*) without being blocked by the blood–brain barrier. These cells dramatically change their shape into 
a ramified morphology once they enter the parenchyma. Therefore, immune cells can interact with brain parenchymal cells via at least four types of histological 
architecture. This figure is a modification of copyrighted material permitted by Nature Publishing Group (31), License Id: 3917450680042.
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spatial water maze task (51), contextual fear conditioning (52), 
context discrimination memory (53), etc. are dependent on hip-
pocampal function. However, LPS does not cross the BBB unless 
it is pathologically impaired (54). The amount of LPS entering 
brain parenchyma is only about 0.025% of an intravenously 
administered dose, which suggests that most effects induced by 
acute peripheral administration of LPS are not mediated through 
receptors expressed by brain parenchymal cells (55). Thus, how 
LPS outside the BBB mediates changes inside the brain is one 
of the most important remaining contemporary questions. Four 
possible routes by which the CNS and immune system might 
interact with each other have been proposed (56): a neural route 
via sympathetic or vagus nerves (57), CVOs, transport by cellular 
components that form the BBB (58), and secretion by vascular 
endothelial cells (58).
Microglial involvement in the 
Communication of the immune system 
with the Brain
Microglia are known to be activated by systemic LPS adminis-
tration (59). Intravenous injection of LPS (1–5 mg/kg) into rats 
induces a morphological transition of microglia to macrophage-
like cells in the hypothalamus, thalamus, and brainstem 8–24 h 
after LPS injection (60). A systematic review of 51 studies that 
performed animal experiments has reported a relationship 
between systemic inflammation and microglial activation (61). 
Most studies have shown that microglia are activated time-
dependently following single systemic challenge of mice and 
rats with LPS. What is required to induce CNS inflammatory 
responses during endotoxemia is the expression of toll-like recep-
tor 4 (TLR4) on non-hematopoietic, intracranial resident cells 
located in the leptomeninges, choroid plexus and CVOs, cells 
along blood vessels, ependymal cells, and parenchymal microglia 
(62). Interestingly, non-parenchymal cells that are involved in 
sustained brain inflammation are located at the brain–immune 
interface as defined by our own studies using BMT (29, 30).
Depending on the experimental paradigm, activated microglia 
induced by systemic LPS administration can be neuroprotective. 
Daily intraperitoneal (i.p.) injections of LPS (1 mg/kg) for four 
consecutive days induce microglial activation that is detectable 
24  h after the last injection, whereas microglial activation is 
not detectable at 24 h after a single i.p. injection of LPS (1 mg/
kg) (63). Microglia thus activated by four daily i.p. injections of 
LPS are skewed toward an M2-like phenotype and participate in 
neuroprotection against experimental brain injury (63). It has 
been demonstrated that the activation of microglia induced by 
this LPS pretreatment paradigm is also independent of TLR4 on 
hematopoietic cells (63). Nevertheless, the mechanism connect-
ing systemic inflammatory challenge and microglial activation 
has not been well documented (61).
importance of astrocytic endfeet in the 
endotoxemia-induced Hippocampal 
responses
In our second set of experiments described in the present arti-
cle that has been originally published in Ref. (31), we induced 
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endotoxemia by a single i.p. injection of LPS at a dose of 3 mg/
kg into mice, and by using Luminex multiplex assay technology, 
we identified cytokines that showed a change in concentration 
in the hippocampus and spleen. We then immunohistologically 
identified cells involved in the elevation of hippocampal cytokine 
levels (31). The concentration of at least 10 cytokines increases in 
the hippocampus in response to endotoxemia. Leptomeningeal 
stromal cells, choroid plexus stromal cells, and choroid plexus 
epithelial cells produce CC-motif ligand (CCL)2, CXC-motif 
ligand (CXCL)1, CXCL2, and IL-6 transiently at 4  h after LPS 
injection. Hippocampal vascular endothelial cells produce CXCL1 
at 4 h after LPS injection. Importantly, these cells are located at the 
brain–immune interface but not in the brain parenchyma.
Cytokine whose concentrations are increased in the hip-
pocampus at later than 4 h and at up to 24 h after LPS injection 
are produced chiefly by brain parenchymal astrocytes (31). Based 
on the fact that astrocytic endfeet express receptors for CCL2, 
CXCL1, CXCL2, and IL-6, it is considered that astrocytes are 
exposed to these cytokines via endfeet that are located in close 
apposition to cytokine-producing cells at the brain–immune 
interface. Stimulation of astrocytic endfeet with cytokines released 
by interface cells is very likely to result in inducing astrocytes to 
release another group of cytokines including CXCL10, CCL11, 
and granulocyte-colony stimulating factor (G-CSF) into the 
hippocampal interstitium (31). An increase in cytokines in the 
hippocampus occurs later than in the spleen, suggesting that the 
brain requires more steps than the spleen to produce cytokines in 
response to endotoxemia.
Astrocytes can produce CCL11 in response to endotoxemia. 
CCL11 in the brain is known to impair learning and memory 
(64), although this chemokine is known as a strong eosinophil 
chemoattractant that mediates allergic diseases. CCL11 also 
promotes the migration of microglia and induces microglia to 
produce reactive oxygen species, thereby enhancing excitotoxic 
neuronal death (65). Thus, astrocyte-derived CCL11 in our 
model may exert harmful effects on the hippocampal functions, 
leading to behavioral changes and memory impairment.
Astrocytes can also produce G-CSF in response to endo-
toxemia. Although G-CSF exerts neuroprotective actions on 
cerebral ischemic damage by promoting neuronal progenitor 
responses (66, 67), systemic injection of G-CSF into uninjured 
mice enhances the proliferation of microglia in the intact hip-
pocampus (68). The latter observation suggests that G-CSF may 
act as a growth factor for microglia. Thus, astrocyte-derived 
G-CSF in our model may enhance the proliferation of microglia 
in the hippocampus, resulting in behavioral changes and memory 
impairment.
CXCL1 is produced by vascular endothelial cells. CXCR2, a 
receptor for CXCL1, is expressed on astrocytic perivascular end-
feet. Given that cell–cell interactions with cytokines as mediators 
occur between cells located close to each other and that vascular 
endothelial cells are in close apposition to perivascular astrocytic 
endfeet that cover most of the perivascular surface of the cerebral 
microcirculation, a relationship between CXCL1 production by 
endothelial cells and CXCR2 expression by astrocytic endfeet 
appears reasonable. In the same manner, CCL2, CXCL1, CXCL2, 
and IL-6 are produced by leptomeningeal stromal cells, and the 
receptors for these cytokines are expressed on subpial astrocytic 
endfeet. A relationship between these cytokines and their recep-
tors also appears to be reasonable given the close apposition 
between leptomeningeal cells and subpial astrocytic endfeet that 
line the entire brain surface.
In addition to these cell–cell interactions, choroid plexus epi-
thelial cells may also release cytokines into the ventricular space 
and choroid plexus stromal cells may release cytokines into the 
subarachnoid space. A report in which the flow of subarachnoid 
CSF into and through the brain interstitium was investigated (8) 
has indicated that fluorescent tracers with low molecular weight 
(759 Da) infused in subarachnoid CSF move quickly throughout 
the brain interstitium. Tracers with intermediate molecular 
weight (3  kDa) infused in subarachnoid CSF concentrate in 
the paravascular space but also enter the brain interstitium to 
a limited extent from the paravascular space and from the pial 
surface. By contrast, large molecular weight tracers (2,000 kDa) 
infused in subarachnoid CSF are confined along paravascular 
space and do not enter surrounding interstitial space. Since the 
molecular weights of CCL2, CXCL1, CXCL2, and CXCL10 are 
approximately 7–8 kDa and that of IL-6 is approximately 18 kDa, 
expected movements of these cytokines in subarachnoid space 
are likely similar to those of tracers with intermediate molecular 
weight. Therefore, these cytokines may infiltrate the interstitium 
of paravascular and subpial regions.
Another possible pathway for cytokine flow from the choroid 
plexus into the hippocampus involves the attachments of choroid 
plexus (29, 30). Given that the hippocampus holds the attach-
ments of choroid plexus at the fimbria, cytokines released by 
choroid plexus stromal cells may flow into the fimbria through 
the attachments of choroid plexus.
Thus, cells of the brain–immune interface respond to endotox-
emia with cytokine-mediated signals earlier than hippocampal 
parenchymal cells. In the parenchyma, astrocytes play a key role 
in responding to these signals by using endfeet with cytokine 
receptors that are located in close apposition to the interface cells. 
These results are summarized in a cartoon illustration in Figure 4. 
How the responses by astrocytes are relayed to microglia awaits 
further studies.
CLiniCaL reLeVanCe oF BasiC 
stUdies oF tHe strUCtUre and 
FUnCtion oF tHe Brain–iMMUne 
interFaCe
perturbed Brain–immune interaction in a 
Wide Variety of neurological and 
psychiatric diseases
Bone marrow-derived cells that enter the brain parenchyma 
increase in number in animal models of ischemic brain injury 
(69–71) and status epilepticus (72, 73), as well as in animal mod-
els of neurodegenerative diseases such as AD (74), Parkinson’s 
disease (PD) (75, 76), and amyotrophic lateral sclerosis (ALS) 
(77, 78). In experimental allergic encephalomyelitis, the choroid 
plexus is known as the CNS lymphocyte entry point (79). In a 
FigUre 4 | schematic illustration of the possible cytokine flow pathway by which systemic inflammation changes the brain cytokine 
microenvironment. In response to systemic inflammation induced by intraperitoneal injection of lipopolysaccharide (LPS), hippocampal vascular endothelial cells, 
leptomeningeal stromal cells, choroid plexus stromal cells, and choroid plexus epithelial cells produce early cytokines (such as CCL2, CXCL1, CXCL2, and IL-6) at 
4 h after LPS injection (red arrows). The receptors for these cytokines are expressed by astrocytic endfeet that are localized in close apposition to vascular 
endothelial cells and leptomeningeal cells. Thus, cytokine-mediated cell–cell interactions occur between the endothelial cells and the perivascular astrocytic endfeet, 
and between the leptomeningeal stromal cells and the subpial astrocytic endfeet. In addition, cytokines produced by choroid plexus stromal cells and epithelial cells 
may flow into the cerebrospinal fluid, and those produced by choroid plexus stromal cells may also flow into the brain parenchyma via the attachments of choroid 
plexus (red arrows). Thereafter, astrocytes produce late cytokines (such as CCL11, CXCL10, and granulocyte-colony stimulating factor) at 4–24 h after LPS injection 
(black arrows). An initial step in the activation of stromal cells in the leptomeninges and choroid plexus, and in the activation of choroid plexus epithelial cells, may be 
triggered by nearby myeloid cells, although this remains to be proven (black arrows with dotted line). This figure is a reproduction of copyrighted material permitted 
by Nature Publishing Group (31), License Id: 3917450680042.
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stroke model, bone marrow-derived perivascular, meningeal, 
and choroid plexus macrophages play an integral role in the 
inflammatory cascade (80). Repeated social defeat (81) and 
LPS-induced peripheral immune activation increases recruit-
ment of bone marrow-derived monocytes into the brain (82). 
Recruitment of bone marrow-derived cells with the monocyte/
macrophage lineage into the brain parenchyma is also enhanced 
in the senescence-accelerated mouse prone 10 (SAMP10), an 
animal model of human brain aging (83). The diencephalic struc-
tures located along the midline at the dorsal and ventral edges 
such as the choroid plexus epithelium, ependyma, astrocytic 
processes in the attachments of choroid plexus, periventricular 
astrocytes, tanycytes, and neurons of the median eminence and 
hypothalamus contribute to elevated tissue concentrations of 
CXCL1, CCL11, G-CSF, and CXCL10 in the brain. Changes in the 
cytokine profile accelerate the dynamics of immune cells migrat-
ing from the bone marrow to the diencephalon in SAMP10 mice.
Microglia are thought to be responsible for neuronal cell 
death in AD, PD, and ALS (84). Most published articles on 
microglia in these neurodegenerative diseases link activation 
of microglia with proinflammatory cytokine production (85). 
However, the presence of “dystrophic (senescent) microglia” in 
aged human brain has been proposed more recently (86). Given 
that microglia are neuroprotective, it is reasonable to consider 
that aging-related, progressive microglial degeneration, and loss 
of microglial neuroprotection rather than induction of microglial 
activation contributes to the onset of sporadic AD (86). This idea 
is also supported by our own findings on microglial aging in 
SAMP10 mice (87).
Proinflammatory status associated with cytokine imbalance is 
involved in a wide variety of psychiatric diseases such as autism 
spectrum disorders (ASDs) (88), schizophrenia (89), and depres-
sion (90). Autopsy findings of postmortem brains from individu-
als with ASD have indicated prominent microglia activation as 
well as increased production of inflammatory cytokines such as 
interferon (IFN)-γ, IL-1β, IL-6, TNF-α, and CCL2 in the brain 
tissue and CSF (88). Schizophrenia is associated with disruption 
of the cytokine milieu and the propensity for the production 
of proinflammatory cytokines (89). Acute psychotic episode is 
associated with increased serum concentrations of IL-6, TNF-α, 
IL-1β, and IFN-γ (89). Patients with major depression exhibit 
increased serum/plasma concentrations of IL-6 and C-reactive 
protein as well as elevated levels of IL-1β and TNF-α in peripheral 
blood and CSF (90).
Unlike multiple sclerosis, the archetypal inflammatory 
disease of the CNS in which an immune assault on the brain 
and spinal cord damages myelin sheaths and axons, most neu-
rodegenerative and psychiatric diseases lack remarkable inflam-
matory cell infiltrates in the CNS (84, 91). Although monocytes 
and some other immune cells such as CD4+ and/or CD8+ T 
cells infiltrate the brain in neurodegenerative diseases, all of 
these immune cells appear in small numbers (84). Therefore, the 
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involvement of immune abnormalities in aging and neurode-
generative diseases as well as psychiatric disorders is associated 
with imbalance in cytokine milieu rather than brain infiltration 
of inflammatory cells.
sepsis-associated encephalopathy (sae)
Sepsis is the excessive systemic inflammatory reaction of an organ-
ism in response to an infection (92, 93). Septic encephalopathy or 
SAE is a multifactorial syndrome, which is characterized as diffuse 
brain dysfunction such as delirium, cognitive impairments, and 
loss of consciousness (94, 95). Importantly, patients develop SAE 
without clinical or laboratory evidence of direct brain infection or 
other types of encephalopathy (e.g., hepatic or renal encephalopa-
thy) (94, 95). Instead, SAE is induced in the brain of an organism 
as a result of responses to systemic inflammatory changes. SAE 
is the most frequent type of encephalopathy encountered in the 
intensive care unit (92) and is present in about 20–30% of patients 
with sepsis. SAE often occurs before the failure of other organs 
(96) and, when present, it increases the mortality rate (97). In 
spite of the clinical importance of SAE, there presently exists 
no effective therapy that has been developed to specifically treat 
SAE in clinical settings (92), and only supportive therapy for the 
underlying disease is administered.
Although a case–control study in which the brain tissue of 13 
patients with sepsis was compared with that of 17 controls reported 
a significant increase in the number of CD68-immunopositive 
activated microglia in the gray matter of septic patients (98), 
pathophysiological mechanisms of SAE have been proposed based 
chiefly on data obtained from experimental models. Disruption 
of the BBB due to loosened tight junctions of endothelial cells and 
detachment of the pericytes of hippocampal capillaries may play a 
role in SAE (99). Upregulation of intercellular adhesion molecule 
1 during SAE (100) together with increased BBB permeability 
may induce circulating monocytes to adhere to the endothelium 
and pass into the surrounding tissues, where they proliferate and 
expand the population of perivascular macrophages (96).
In relatively early phase of sepsis, possible changes in the brain 
microcirculation may cause hypoxia–ischemia, which may lead to 
SAE through the upregulation of inflammatory gene transcripts 
including transcripts of TNF-α, IL-1β, and inducible nitric oxide 
synthase. TNF-α has been suggested to be a key inflammatory 
mediator. TNF-α can be produced intrinsically in the brain, it 
regulates aquaporin, and it alters the transport of water into the 
brain resulting in edema (101). Cytokines, together with reactive 
oxygen species and nitric oxide, can also mediate a decrease in 
mitochondrial ATP generation, resulting in an energy deficit 
in early sepsis (102–105). Another possibility is that there is an 
elevation in the levels of complement activation products during 
sepsis, which can cause brain tissue injury, and which, again, 
occurs via the release of cytokines (106).
Our experimental data indicating that cells of the brain–
immune interface respond to endotoxemia with cytokine-
mediated signals earlier than brain parenchymal cells and that 
parenchymal astrocytes play a key role in responding to these 
signals by using cytokine receptors on endfeet located in close 
apposition to the interface cells (31) would contribute to an 
understanding of the initial events leading to SAE.
preterm Brain injury
Neonatal mortality and morbidity has been improved in the past 
half century. However, brain injury that occurs during the perina-
tal period is still a common cause of lifelong neurodevelopmental 
disabilities including cerebral palsy. The rates of cerebral palsy 
are not declining and may even be increasing in some western 
countries (107, 108). Therefore, the pathophysiology of perinatal 
brain injury remains a point of scientific debate. Although the 
etiology may be multifocal, hypoxia–ischemia, infection/inflam-
mation, and excitotoxicity are considered important causes of 
perinatal brain injury (109). Experimental studies have indicated 
that antecedents such as infection/inflammation, intrauterine 
growth restriction, or preexposure to hypoxia modulate brain 
vulnerability (110, 111). Very recently, one of the mechanisms 
underlying the causal relationship between maternal immune 
activation and autistic behavioral abnormalities in the offspring 
has been revealed (112). Maternal immune activation increases 
IL-6 in the serum of pregnant mice, which leads to an increase 
in TH17 cells in maternal blood. These cells release IL-17, which 
crosses the placenta and increase the expression of IL-17 recep-
tors in the offspring’s brain. This phenomenon in turn leads to 
autistic abnormalities in the offspring.
Brain injury evolves over time. Acute cerebral hypoxia/
ischemia serves to cause depletion of tissue energy reserves, 
resulting in primary insult, which is often followed by tran-
sient restoration of energy metabolism upon reoxygenation. 
Thereafter, delayed or secondary cerebral energy failure parallels 
a decrease in tissue glucose metabolism and development of cell 
injury (113). Even after secondary cell death has subsided, effects 
on the brain persist including sensitization to inflammation or 
injury, increased seizure susceptibility, impaired oligodendro-
cyte maturation and myelination, and persistent inflammation 
and gliosis (114–116). Tertiary brain damage is defined in such 
situations as “injury caused by a long-persisting process follow-
ing brain insult that worsens outcome, predisposes to further 
injury, or prevents repair/regeneration” (109). Tertiary brain 
injury underlies cerebral palsy (116), schizophrenia (117), and 
ASD (118).
An estimated 500,000 babies are born preterm (before 37 
completed weeks of gestation) every year in the United States. 
Chorioamnionitis is a common cause of preterm birth. Clinical 
chorioamnionitis is characterized by maternal fever, leukocytosis, 
tachycardia, uterine tenderness, and prerupture of membranes 
(119), whereas subclinial chorioamnionitis is asymptomatic and 
is defined by inflammation of the chorion, amnion, and placenta 
(120). Subclinial chorioamnionitis is more common than clinical 
chorioamnionitis. Chorioamnionitis is often associated with a fetal 
inflammatory response syndrome that is defined by increased sys-
temic inflammatory cytokine concentrations, funisitis, and fetal 
vasculitis (120). The fetal inflammatory response syndrome leads 
to a long-term adverse outcome such as impaired fetal cardiac 
function, chronic lung disease, retinopathy of prematurity, and 
lifelong neurological impairments including cerebral palsy, men-
tal retardation, and learning deficits (120–123). Periventricular 
leukomalacia (PVL) is the predominant form of brain injury and 
the leading known cause of cerebral palsy and cognitive deficits 
in preterm infants (124).
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Several animal models have been introduced for studies of 
preterm brain injury. The features, advantages, and disadvantages 
of each animal model of preterm birth are summarized elsewhere 
(125). Hypoxia–ischemia mouse, rat, and pig models and chronic 
hypoxia mouse and rat models have been utilized for the study of 
disorders in very low birth weight infants. The global mechanism 
by which perinatal hypoxia alters development is through a delay 
in the maturation of affected cell types, including astrocytes, 
oligodendrocytes, and neurons (125). Delays in oligodendrocyte 
maturation cause delayed myelination, which is typical of preterm 
white matter damage. By contrast, a proinflammatory status with 
cytokine imbalance has been reported in PVL (124, 126, 127). In 
this regard, LPS-induced inflammation mouse, rat, rabbit, and 
sheep models and an IL-1β administration mouse model are also 
useful for studies of preterm brain injury (125, 128).
An especially important characteristic of preterm newborns 
is that, when they develop systemic inflammation, they have the 
capacity to prolong the inflammation, resulting in intermittent 
or sustained systemic inflammation, and thereby increasing the 
risk of brain damage (129). Intermittent or sustained systemic 
inflammation contributes more to adverse neurodevelopmental 
outcomes in preterm infants than shorter duration inflammation 
(119). Therefore, future studies should address how prolonged 
systemic inflammation in preterm infants affects immature 
brains and causes long-lasting neurodevelopmental deficits. 
Since human babies at 25, 30, and 35  weeks of gestational age 
correspond to rodent pups at postnatal day 3 (P3), P7, and 
P10, respectively (125), newborn rodents treated with multiple 
systemic LPS injections can be a good model of intermittent 
or sustained systemic inflammation in preterm infants. The 
mechanism that connects systemic inflammation and microglial 
activation in preterm brains would be an especially promising 
avenue of research.
ConCLUsion
The leptomeninges, choroid plexus stroma and epithelium, 
attachments of choroid plexus, perivascular space, CVOs, and 
astrocytic endfeet construct the histological architecture that 
provides a location for intercellular interaction between bone 
marrow-derived myeloid lineage cells and brain parenchymal 
cells under non-inflammatory conditions or at early stages 
of systemic inflammation during which the BBB is relatively 
preserved and the brain parenchyma exhibit no necrotic tissue 
damage. This histological architecture functions as the interface 
between the brain and the immune system to relay systemic 
inflammation-induced microenvironmental molecular events 
to the brain parenchyma. An understanding of how brain 
parenchymal cells, particularly microglia, respond to signals 
conveyed in this manner awaits further studies. It is essential that 
the mechanisms underlying the intercellular interactions among 
brain parenchyma cells as well as those between immune cells 
and brain cells be unraveled. Future investigations of these issues 
would enhance our understanding of the pathogenesis of SAE 
and of preterm brain injury.
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